Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s572677 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Khlood Mohammad Aldossary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Paroxetine. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Despite advances in pharmacological interventions for rheumatoid arthritis (RA), a subset of patients continues to experience disease activity, highlighting the need for adjunctive therapeutic strategies.
Objective
To assess the therapeutic efficacy of paroxetine when administered as adjuvant therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis (RA).
Methods
In this randomized, double-blind, clinical trial, one hundred patients were randomized in 1:1 ratio to receive either csDMARDs including methotrexate plus placebo (control group) or paroxetine (paroxetine group). The primary endpoint was the change in Disease Activity Score using 28 joint counts (DAS-28) [Tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP), visual analogue scale (VAS)] at three months. Secondary endpoints included multidimensional health assessment questionnaire [morning stiffness (MS), pain, fatigue, physical functioning (PF)].
Results
After treatment, both groups demonstrated significant within-group improvements in TJC, SJC, VAS, and DAS-28, with superior improvements observed in the paroxetine group (p = 0.016, 0.0006, 0.03, and 0.005, respectively). CRP showed no significant change in the control group (p = 0.933). Paroxetine group showed significant reductions in MS, pain, and fatigue (p = 0.024, 0.03, and 0.006, respectively) compared with the control group, while PF were significant within groups but not between groups (p = 0.208). Adverse events were comparable, except for a higher incidence of decreased libido in the paroxetine group.
Conclusion
Adjunctive paroxetine significantly improved clinical and patient-reported outcomes in mild and moderate RA patients and was generally well tolerated, supporting its potential as an effective adjunctive therapy. The relatively small single-center sample, the exclusion of severe RA patients, the short disease duration, the low seropositivity, absence of mental health assessment, the possibility of overlapping with secondary pain mechanisms (eg, central sensitization or early fibromyalgia features) may limit the generalizability of the findings to broader and more diverse patient populations. Trial Registration Identifier: NCT06231745.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, Menoufia, Egypt.
- Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
- Biochemistry Department, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Egypt.
- Department of Rheumatology, Rehabilitation, and Physical Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Department of Rheumatology, Rehabilitation, and Physical Medicine, Faculty of Medicine, Sohag University, Sohag, Egypt.
ORCID-Profile: Mahmoud S Abdallah, Mostafa M Bahaa
Zitieren
APA
Aldossary, K. M., Abdallah, M. S., Mosalam, E. M., Kamal, N., Saif, D. S., Elsayed, S. A., Afifi, N., Zakaraia, H. G., Khrieba, M. O., & Bahaa, M. M. (2025). Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s572677
Vancouver
Aldossary KM, Abdallah MS, Mosalam EM, Kamal N, Saif DS, Elsayed SA, et al. Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s572677
BibTeX
@article{Aldossary2025,
author = {Aldossary, Khlood Mohammad and Abdallah, Mahmoud S and Mosalam, Esraa M and Kamal, Noha and Saif, Dalia S and Elsayed, Sahar Abdel-Rahman and Afifi, Naglaa and Zakaraia, Haitham G and Khrieba, Mohannad O and Bahaa, Mostafa M},
title = {Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s572677}
}
EUVIMED